Engineers Gate Manager LP Reata Pharmaceuticals Inc Transaction History

Engineers Gate Manager LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$22.15 - $42.11 $256,253 - $487,170	11,569 New	11,569 $439,000
Q2 2022 Aug 15, 2022	SELL	$20.71 - $36.5 $79,671 - $140,415	-3,847 Reduced 14.4%	22,877 $695,000
Q1 2022 May 16, 2022	BUY	$24.12 - $39.6 $38,495 - $63,201	1,596 Added 6.35%	26,724 $875,000
Q4 2021 Feb 14, 2022	BUY	$25.61 - $110.96 $643,528 - $2.79 Million	25,128 New	25,128 $663,000
Q2 2020 Aug 17, 2020	SELL	$126.3 - $176.56 $1.09 Million - $1.53 Million	-8,647 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$124.16 - $247.74 $1.07 Million - $2.14 Million	8,647 New	8,647 $1.25 Million
Q1 2019 May 15, 2019	SELL	$51.9 - $101.79 $1.23 Million - $2.42 Million	-23,727 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$48.76 - $76.44 $799,030 - $1.25 Million	-16,387 Reduced 40.85%	23,727 $1.33 Million
Q3 2018 Nov 01, 2018	BUY	$35.64 - $92.06 $572,770 - $1.48 Million	16,071 Added 66.84%	40,114 $3.28 Million
Q2 2018 Aug 03, 2018	BUY	$19.94 - $40.96 $479,417 - $984,801	24,043 New	24,043 $841,000

62.7K

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

Stay updated on Engineers Gate Manager LP with notifications on news.